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Setting the scene
Invasive fungal infections (IFI) continue to constitute a major
challenge to treating physicians as a result of the increased
number of cases and the high mortality. Close collaboration
among physicians, mycologists and pharmacologists is neces-
sary in order to exploit new treatment and diagnostic modal-
ities and to optimize the use of those already available, with
the ultimate goal of improving the outcome of IFI. In this
issue of the journal, we present reviews from representatives
of each of these specialties.
Hope and Drusano [1] review the approach of predicting
the optimal dosing of systemic antifungals based upon experi-
mental models and pharmacokinetic/pharmacodynamic analy-
sis. It is difﬁcult to design and conduct clinical trials that, in a
comprehensive way, provide exhaustive data on dosing regi-
mens and outcome relationships in a disease entity where
outcome is inﬂuenced by a number of factors in addition to
the infection itself. Consequently, clinical experience over
time may reveal that initial dosing regimes are suboptimal.
Graninger et al. [2], as early as 1993, demonstrated the cor-
relation between ﬂuconazole dosing and clearance of the
blood stream during candidaemia, comparing 5 and 10 mg/kg
per day. The response rate was 60% vs. 83%, the failure to
clear candidaemia 2/30 vs. 0/30 and the attributable mortality
8/30 vs. 1/30 (p 0.0258). Clancy et al. [3], in 2005, demon-
strated the correlation between dose/MIC and treatment
outcome for candidaemia and ﬂuconazole, with an increasing
number of failures occurring when the dose/MIC ratio fell
below 50 (p 0.0003). Subsequently, Pai et al. [4] also incorpo-
rated the weight and showed a more than three-fold differ-
ence in mortality upon comparing patients with a dose/kg/
MIC between 0–5 and >10, respectively (p 0.03). Finally, Ga-
rey et al. [5] demonstrated that, in a cohort of 206 candidae-
mic patients from four medical centres in the USA, 55% of
the patients received inadequate empirical dosing (<400 mg
or <6 mg/kg) and 47% of the patients did so after species
identiﬁcation based on the guidelines of the Infectious Dis-
eases Society of America (400 mg or 6 mg/kg per day for
infections caused by species other than Candida glabrata and
Candida krusei and 800 mg or 12 mg/kg for C. glabrata infec-
tions). As a result of such studies, the recommended daily
dose has been increased and awareness has emerged that
overweight patients and patients with C. glabrata infections
are at risk of being underdosed, despite the current recom-
mendations. As illustrated in this theme section, experimen-
tal models and pharmacokinetic/pharmacodynamic analysis
can contribute to a better prediction of optimal dosing regi-
mens with respect to size and frequency of doses [1].
The highest incidence of candidaemia per age group is
observed in the neonatal population, with incidence rates of
10–40/100 000 population [6–9] and children with underlying
haematological disease are at risk of invasive mould infec-
tions [10]. Yet, the diagnosis and management of invasive
fungal infections in the paediatric setting is less well studied
than in adults. A number of new antifungal compounds have
been launched over the recent decades and their role in the
management of adult infections has been established. How-
ever, not all of these compounds have been thoroughly stud-
ied in children and, because of the different pharmacokinetic
proﬁles, the adult dosing regimens cannot be directly trans-
lated. The diagnostic armamentarium has evolved consider-
ably over the recent decades, with improved culture media,
rapid species identiﬁcation tests and surrogate markers for
invasive Candida and Aspergillus infections having been devel-
oped and marketed. The diagnostic sensitivity of antigen and
PCR testing depends largely on the number of samples taken
and, in both cases, testing at least twice weekly during risk
periods is recommended and associated with higher sensitiv-
ity [11,12]. Furthermore, the beneﬁt of such screening regi-
mens in terms of more targeted antifungal treatment and
reduced cost has been demonstrated in several studies [13–
15]. Yet still a number of infections go undiagnosed [16] or
are diagnosed at a late stage, with a consequently poorer
outcome [17,18]. Part of this is probably the result of fungi
being slower growing and present intermittently, or in lower
amounts, in the clinical samples compared to bacteria.
However, part of the reason may also be that these new
markers are not used optimally, if at all, or, although labora-
tories perform well in traditional external quality assessment
schemes, and thus do not lack professional skills, the level of
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routine testing may be considerably less impressive [19]. In
this theme section, an overview of the advances in detection
and rapid species identiﬁcation applicable for the routine
diagnostic laboratory is provided, with a focus on those
relevant in the paediatric setting. Subsequently, the current
antifungal treatment options for neonates and children are
discussed in light of the antifungal spectrum of the available
agents and the speciﬁc pharmacokinetic properties in differ-
ent age groups [20].
The third review focuses on new trends relating to inva-
sive fungal infections [21]. The epidemiology and outcome of
fungal infections depends on the balance among the three
main players: (i) the susceptibility of the host; (ii) the patho-
genicity and susceptibility of the fungus; and (iii) the timing
and concentration at the infectious site of the antifungal
compound. Changes in any of these players inﬂuence the
number of infections as well as their outcome. Advances in
the treatment of cancer, including new immune-modulating
agents, advanced and complicated surgical procedures, and a
growing population of elderly people, are well-known factors
that have contributed to an increased number of patients
being at risk.
In addition, there is increasing evidence that our genetic
makeup determines the inherent susceptibility to invasive
fungal infections [22–25]. Characterization of such inborn
risk factors may help us in the future to identify patients
who are at particular risk, and thus, hopefully, prevent
infections through closer monitoring and also create inter-
ventions that counteract the increased susceptibility.
Acquired resistance in species normally susceptible to
antifungal agents occurs at a much lower rate than in bacte-
ria, the main reason probably being that resistance genes are
not transmitted among fungi as they are via plasmids and
bacteriophages among bacteria. Thus, the resistance mecha-
nism has to arise in the individual fungal cell and only by cell
division does it lead to an increased proportion of resistant
isolates. In agreement with this, reported rates of acquired
resistance have constantly been at a low level (e.g. 1–3% for
ﬂuconazole and C. albicans) despite the high use of azoles
in the primary and secondary heath care sector [26,27].
However, a number of reports have documented emergence
of Aspergillus and Candida isolates with resistance to azoles
or echinocandins in patients on antifungal treatment, and
new underlying resistance mechanisms continue to be char-
acterized. Furthermore, recent studies have demonstrated an
emergence of azole-resistant Aspergillus fumigatus in the
Netherlands, with resistant isolates being found in azole
naı¨ve patients as well as in the environment sharing a
common resistance mechanism [28]. Similarly, azole resis-
tance has been detected in Candida isolates from the surface
of non-organic fruit in contrast to organic fruit. These
ﬁndings suggest that azole use in agriculture may also be a
driving factor for resistance [29]. Finally, rare fungal species
emerge as human pathogens posing diagnostic and treatment
challenges. Erjavec et al. [21] provide an overview on these
new trends as a foreshadow of future challenges.
Indeed, we hope that this theme section will serve as an
update on pressing issues in the ﬁeld of medical mycology,
illustrate past achievements and, at the same time, recognize
the challenges ahead that need to be solved in a multi-disci-
plinary effort.
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